Literature DB >> 21233638

Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.

Agnès Depatureaux1, Charlotte Charpentier, Marie Leoz, Guillemette Unal, Florence Damond, Anfunbom Kfutwah, Aurélia Vessière, François Simon, Jean-Christophe Plantier.   

Abstract

BACKGROUND: HIV-1 group O (HIV-O) is characterized by a high genetic divergence from HIV-1 group M viruses. Little is known about the therapeutic impact of this diversity. The aim of this study was to assess in a large series of samples (1) the genotypic impact of natural polymorphism of the HIV-O reverse transcriptase and protease genes; and (2) the predictive value of resistance interpretation algorithms developed for HIV-1 group M when used for highly mutated HIV-O viruses.
METHODS: Sixty-eight antiretroviral-naive and 9 highly antiretroviral-experienced HIV-O-infected patients were included. The viruses were sequenced and resistance-associated mutations were identified using 3 different algorithms (Agence Nationale de Recherches sur le SIDA et les hépatites virales, Rega, Stanford).
RESULTS: All HIV-O samples naturally exhibited the A98G and V179E resistance mutations in the reverse transcriptase region; 54% of samples presented the Y181C mutation, conferring resistance to nonnucleoside reverse transcriptase inhibitors. Twelve minor resistance mutations, present in more than 75% of the protease sequences, led to the different algorithms giving discrepant results for nelfinavir and saquinavir susceptibility. A marked virological response was observed in 8 of the 9 antiretroviral-experienced patients, despite the prediction of limited activity of the combination for 5 to 8 patients according to the algorithm used.
CONCLUSIONS: The high level of natural polymorphism in HIV-O genes, and the important discrepancies between genotypic resistance interpretation and the virological response, emphasize the need for resistance algorithm rules better adapted to HIV-O.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233638     DOI: 10.1097/QAI.0b013e318201a904

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

2.  Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Authors:  Mohan Kumar Haleyur Giri Setty; Jikun Liu; Prerna Mahtani; Panhe Zhang; Bingchen Du; Viswanath Ragupathy; Krishnakumar Devadas; Indira K Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-15       Impact factor: 2.205

3.  HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Authors:  Christian Julian Villabona-Arenas; Jenny Domyeum; Fatima Mouacha; Christelle Butel; Eric Delaporte; Martine Peeters; Eitel Mpoudi-Ngole; Avelin Fobang Aghokeng
Journal:  Infect Genet Evol       Date:  2015-09-11       Impact factor: 3.342

Review 4.  Non-M variants of human immunodeficiency virus type 1.

Authors:  Thomas Mourez; François Simon; Jean-Christophe Plantier
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection.

Authors:  Marie Gueudin; Marie Leoz; Véronique Lemée; Fabienne De Oliveira; Aurélia Vessière; Anfumbom Kfutwah; Jean-Christophe Plantier
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

6.  HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.

Authors:  Agnès Depatureaux; Peter K Quashie; Thibault Mesplède; Yingshan Han; Hannah Koubi; Jean-Christophe Plantier; Maureen Oliveira; Daniela Moisi; Bluma Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

7.  Multiple HIV-1/M + HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon.

Authors:  Fabienne De Oliveira; Thomas Mourez; Aurélia Vessiere; Paul-Alain Ngoupo; Elodie Alessandri-Gradt; François Simon; Dominique Rousset; Jean-Christophe Plantier
Journal:  Retrovirology       Date:  2017-01-13       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.